IRUS Total

Nitric oxide and pulmonary arterial hypertension

File Description SizeFormat 
Nitric oxide and pulmonary arterial hypertension.pdfPublished version2.15 MBAdobe PDFView/Open
Title: Nitric oxide and pulmonary arterial hypertension
Authors: Chester, AH
Yacoub, MH
Moncada, S
Item Type: Journal Article
Abstract: The pathogenesis of pulmonary arterial hypertension remains undefined. Changes in the expression and effects mediated by a number of vasoactive factors have been implicated to play a role in the onset and progression of the disease. The source of many of these mediators, such as nitric oxide (NO), prostacyclin and endothelin-1 (ET-1), is the pulmonary endothelium. This article focus in the role of nitric oxide in PAH, reviewing the evidence for its involvement in regulation of pulmonary a vascular tone under physiological conditions, the mechanisms by which it can contribute to the pathological changes seen in PAH and strategies for the use of NO as a therapy for treatment of the disease.
Issue Date: 30-Jun-2017
Date of Acceptance: 29-May-2017
URI: http://hdl.handle.net/10044/1/64013
DOI: https://dx.doi.org/10.21542/gcsp.2017.14
ISSN: 2305-7823
Publisher: Bloomsbury Qatar Foundation Journals
Journal / Book Title: Global Cardiology Science & Practice
Volume: 2017
Issue: 2
Copyright Statement: © 2017 Adrian H Chester, Magdi H Yacoub, Salvador Moncada. This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Sponsor/Funder: Qatar Foundation
Funder's Grant Number: WHCF_P48739
Publication Status: Published
Conference Place: Qatar
Article Number: 14
Appears in Collections:National Heart and Lung Institute